59346-65-5

Upstream product

• 13086-84-5 di-tert-butyl phosphite 

Downstream Products

• 169565-39-3 di-tert-butyl-4-formyl-2-nitrophenyl phosphate 
• 289051-05-4 phosphoric acid di-tert-butyl ester 2-(2-pentylsulfanyl-acetylamino)-2-phenyl-ethyl ester 
• 857896-73-2 phosphoric acid di-tert-butyl 2-formylphenyl ester 
• 857896-74-3 phosphoric acid di-tert-butyl 2-hydroxymethylphenyl ester 
• 917480-07-0 {2-[4-(di-tert-butoxy-phosphoryloxy)-3-formyl-phenyl]-2-hydroxy-ethyl}-[6-(4-phenyl-butoxy)-hexyl]-carbamic acid tert-butyl ester 
• 169565-43-9 di-tert-butyl-4-(bromomethyl)-2-nitrophenyl phosphate 
• 169565-42-8 di-tert-butyl-4-(chloromethyl)-2-nitrophenyl phosphate 
• 169565-41-7 di-tert-butyl-4-(fluoromethyl)-2-nitrophenyl phosphate 
• 169565-40-6 di-tert-butyl-4-(hydroxymethyl)-2-nitrophenyl phosphate 
• 1056135-43-3 {2-[4-(di-tert-butoxyphosphoryloxy)-3-formylphenyl]-2-oxoethyl}-[6-(4-phenylbutoxy)hexyl]carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

BENZYLPHOSPHATE AND SUBSTITUTED BENZYLPHOSPHATE PRODRUGS FOR TRE TREATMENT OF PULMONARY INFLAMMATION

A prodrug of a corticosteroid, lidocaine or related local anesthetic composition for formulation for delivery by aerosolization to inhibit inflammation in asthmatic lungs is described. The prodrug is preferably formulated in a 5 ml solution of a quarter normal saline having pH between 5.0 and 7.0 for the treatment of respiratory tract inflammation by an aerosol having mass medium average diameter predominantly between 1 to 5 μ produced by nebulization or dry powder inhaler.